CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113516358
- Phone
- (984) 884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-13 | SCHACHLE JOSEPH K Chief Operating Officer | Grant or award | +52,500 | 54,500 | ||
| 2025-03-13 | SCHACHLE JOSEPH K Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2025-03-13 | Zaremba Rabourn Amy SVP of Finance | Grant or award | +39,500 | 113,968 | ||
| 2025-03-13 | Zaremba Rabourn Amy SVP of Finance | Grant or award · Employee Stock Option (right to buy) | +39,500 | 39,500 | ||
| 2025-03-13 | Magrath George Chief Executive Officer | Grant or award | +330,697 | 929,847 | ||
| 2025-03-13 | Magrath George Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +330,697 | 330,697 | ||
| 2025-03-13 | Jhaveri Nirav S. Chief Financial Officer | Grant or award | +52,500 | 194,293 | ||
| 2025-03-13 | Jhaveri Nirav S. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2025-03-13 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Grant or award | +52,500 | 125,807 | ||
| 2025-03-13 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Grant or award · Employee Stock Option (right to buy) | +52,500 | 52,500 | ||
| 2025-03-13 | Hoffmann Bernhard SVP of Corp. Dev. | Grant or award | +29,500 | 185,446 | ||
| 2025-03-13 | Hoffmann Bernhard SVP of Corp. Dev. | Grant or award · Employee Stock Option (right to buy) | +29,500 | 29,500 | ||
| 2025-02-13 | Jhaveri Nirav S. Chief Financial Officer | Shares withheld for taxes | −8,207 | $1.15 | $9K | 141,793 |
| 2025-02-13 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Shares withheld for taxes | −5,193 | $1.15 | $6K | 73,307 |
| 2025-02-04 | Zaremba Rabourn Amy SVP of Finance | Shares withheld for taxes | −8,190 | $1.14 | $9K | 74,468 |
| 2025-02-04 | Hoffmann Bernhard SVP of Corp. Dev. | Shares withheld for taxes | −6,751 | $1.14 | $8K | 155,946 |
| 2025-01-02 | MANUSO JAMES S J Director | Grant or award | +50,222 | 182,259 | ||
| 2025-01-02 | Bennett Jean Director | Grant or award | +34,021 | 134,021 | ||
| 2024-12-26 | Magrath George Chief Executive Officer | Purchase | +100,000 | $0.98 | $98K | 599,150 |
| 2024-12-23 | Magrath George Chief Executive Officer | Grant or award | +6,200 | 499,150 |
Page 5 of 7 · 136 trades